Efficacy and safety of enzyme replacement therapy for mucopolysaccharidosis type I with 100 IU/kg recombinant human a-L-iduronidase (Aldurazyme).

Trial Profile

Efficacy and safety of enzyme replacement therapy for mucopolysaccharidosis type I with 100 IU/kg recombinant human a-L-iduronidase (Aldurazyme).

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 May 2012

At a glance

  • Drugs Laronidase (Primary)
  • Indications Mucopolysaccharidosis I
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 May 2012 New source identified and integrated (Netherlands Trial Register NTR369).
    • 08 May 2012 Status changed from completed to active, no longer recruiting as reported by Netherlands Trial Register record.
    • 16 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top